• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by CARGO Therapeutics Inc.

    11/14/24 5:45:26 PM ET
    $CRGX
    Get the next $CRGX alert in real time by email
    SC 13G/A 1 tm2427620d27_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Cargo Therapeutics, Inc.

    (Name of Issuer)

     

    Common stock, $0.001 par value per share

    (Title of Class of Securities)

     

    14179K 10 1

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

     

    x

     

    ¨

    Rule 13d-1(b)

     

    Rule 13d-1(c)

     

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   14179K 10 1
    1.

    Names of Reporting Persons

     

    Samsara BioCapital, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,415,689 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,415,689 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,415,689 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.6% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           
    (1)This Schedule 13G is filed by Samsara BioCapital, L.P. (“Samsara LP”), Samsara BioCapital GP, LLC (“Samsara GP”) and Dr. Srinivas Akkaraju (“Akkaraju”) (and together with Samsara LP, Samsara GP, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.
    (3)This percentage is calculated based on 45,904,634 shares of Common Stock outstanding as of August 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed by the Issuer with the Securities and Exchange Commission (the “SEC”) on August 12, 2024.

     

    2 

     

     

    CUSIP No.   14179K 10 1
    1.

    Names of Reporting Persons

     

    Samsara BioCapital GP, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,415,689 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,415,689 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,415,689 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.6% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           
    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.
    (3)This percentage is calculated based on 45,904,634 shares of Common Stock outstanding as of August 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed by the Issuer with the SEC on August 12, 2024.

     

    3 

     

     

    CUSIP No.   14179K 10 1
    1.

    Names of Reporting Persons

     

    Dr. Srinivas Akkaraju

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,415,689 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,415,689 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,415,689 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.6% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           
    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
    (2)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.
    (3)This percentage is calculated based on 45,904,634 shares of Common Stock outstanding as of August 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed by the Issuer with the SEC on August 12, 2024.

     

    4 

     

     

    Item 1.
      (a)

    Name of Issuer

     

    Cargo Therapeutics, Inc.

      (b)

    Address of Issuer’s Principal Executive Offices

     

    835 Industrial Road, Suite 400, San Carlos, CA 94070

     
    Item 2.
      (a)

    Name of Person Filing

     

    Samsara BioCapital, L.P. (“Samsara LP”)

    Samsara BioCapital GP, LLC (“Samsara GP”)

    Srinivas Akkaraju (“Akkaraju”)

      (b)

    Address of Principal Business Office or, if none, Residence

     

    c/o Samsara BioCapital, LLC

    628 Middlefield Road

    Palo Alto, CA 94301

      (c)

    Citizenship Entities:

     

     

     

    Individuals:

     

    Samsara LP

     

    Samsara GP

     

    Akkaraju

     

    -

     

    -

     

    -

     

    Delaware

     

    Delaware

     

    United States

      (d)

    Title of Class of Securities

     

    Common Stock, $0.001 par value (“Common Stock”)

      (e)

    CUSIP Number

     

    14179K 10 1

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      Not applicable
     
    Item 4. Ownership

    The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of November 14, 2024:

     

    Reporting
    Persons
      Shares Held
    Directly
       Sole
    Voting
    Power
       Shared
    Voting
    Power (1)
       Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power (1)
       Beneficial
    Ownership (1)
       Percentage
    of Class (2)
     
    Samsara LP   4,415,689    0    4,415,689    0    4,415,689    4,415,689    9.6%
    Samsara GP   0    0    4,415,689    0    4,415,689    4,415,689    9.6%
    Akkaraju   0    0    4,415,689    0    4,415,689    4,415,689    9.6%

     

    (1)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.

     

    (2)This percentage is calculated based on 45,904,634 shares of Common Stock outstanding as of August 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed by the Issuer with the SEC on August 12, 2024.

     

    5 

     

     

    Item 5. Ownership of Five Percent or Less of a Class
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
      Not applicable
     
    Item 9. Notice of Dissolution of Group
      Not applicable
     
    Item 10. Certification
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    6 

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Samsara BioCapital, L.P.

     

    By: Samsara BioCapital GP, LLC  
    its General Partner  
         
    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  

     

     

    Samsara BioCapital GP, LLC

     

    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  
         
         
    /s/ Srinivas Akkaraju  
    Srinivas Akkaraju  

     

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    7 

     

     

    Exhibit(s):

     

    AJoint Filing Agreement

     

    8 

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Cargo Therapeutics, Inc. is filed on behalf of each of us.

     

    Dated: November 14, 2024

     

    Samsara BioCapital, L.P.

     

    By: Samsara BioCapital GP, LLC  
    its General Partner  
         
    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  

     

     

    Samsara BioCapital GP, LLC

     

    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  
         
         
    /s/ Srinivas Akkaraju  
    Srinivas Akkaraju  

     

     

     

    Get the next $CRGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRGX

    DatePrice TargetRatingAnalyst
    1/30/2025Buy → Neutral
    Chardan Capital Markets
    1/30/2025$32.00 → $3.00Buy → Hold
    Jefferies
    1/30/2025$34.00 → $4.00Overweight → Neutral
    Piper Sandler
    1/30/2025Outperform → Mkt Perform
    William Blair
    1/30/2025Overweight → Underweight
    Analyst
    1/30/2025$32.00 → $7.00Buy → Hold
    Truist
    1/30/2025Buy → Neutral
    H.C. Wainwright
    11/26/2024Outperform
    William Blair
    More analyst ratings

    $CRGX
    SEC Filings

    See more
    • SEC Form 8-K filed by CARGO Therapeutics Inc.

      8-K - CARGO Therapeutics, Inc. (0001966494) (Filer)

      6/20/25 5:30:05 PM ET
      $CRGX
    • SEC Form SCHEDULE 13G filed by CARGO Therapeutics Inc.

      SCHEDULE 13G - CARGO Therapeutics, Inc. (0001966494) (Subject)

      5/15/25 3:00:49 PM ET
      $CRGX
    • Amendment: SEC Form SCHEDULE 13G/A filed by CARGO Therapeutics Inc.

      SCHEDULE 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)

      5/14/25 10:45:26 AM ET
      $CRGX

    $CRGX
    Leadership Updates

    Live Leadership Updates

    See more
    • CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      - 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 - - CRG-023 pre-clinical data to be presented at ASH 2024; IND submission anticipated Q1'25 with Phase 1 initiation planned for 2025 - - Anup Radhakrishnan, CFO of CARGO Therapeutics, appointed as COO and CFO - SAN CARLOS, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided a

      11/12/24 4:05:00 PM ET
      $CRGX
    • CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

      – Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Jane Pritchett Henderson to its Board of Directors. Ms. Henderson will also serve as a member of the audit and compensation committees. "Jane's appointment exemplifies CARGO's ongoing commitment to strong corporate g

      6/4/24 4:05:00 PM ET
      $CRGX
    • CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

      - 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) --  CARGO Therapeutics, Inc. (NASDAQ

      5/14/24 4:05:00 PM ET
      $CRGX

    $CRGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CARGO Therapeutics downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded CARGO Therapeutics from Buy to Neutral

      1/30/25 7:52:27 AM ET
      $CRGX
    • CARGO Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded CARGO Therapeutics from Buy to Hold and set a new price target of $3.00 from $32.00 previously

      1/30/25 7:51:56 AM ET
      $CRGX
    • CARGO Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded CARGO Therapeutics from Overweight to Neutral and set a new price target of $4.00 from $34.00 previously

      1/30/25 7:51:20 AM ET
      $CRGX

    $CRGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Huber Reid M

      4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)

      6/20/25 5:43:27 PM ET
      $CRGX
    • SEC Form 4 filed by Director Bassan Abraham

      4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)

      6/20/25 5:41:36 PM ET
      $CRGX
    • SEC Form 4 filed by Director Dhingra Kapil

      4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)

      6/20/25 5:40:59 PM ET
      $CRGX